JP2021514958A5 - - Google Patents
Info
- Publication number
- JP2021514958A5 JP2021514958A5 JP2020544488A JP2020544488A JP2021514958A5 JP 2021514958 A5 JP2021514958 A5 JP 2021514958A5 JP 2020544488 A JP2020544488 A JP 2020544488A JP 2020544488 A JP2020544488 A JP 2020544488A JP 2021514958 A5 JP2021514958 A5 JP 2021514958A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- nr1r2
- nr1c
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024016079A JP7820423B2 (ja) | 2018-02-23 | 2024-02-06 | 選択的なタンパク質分解を誘導するための低分子およびその使用法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634679P | 2018-02-23 | 2018-02-23 | |
| US62/634,679 | 2018-02-23 | ||
| PCT/US2019/019180 WO2019165229A1 (en) | 2018-02-23 | 2019-02-22 | Small molecules for inducing selective protein degradation and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016079A Division JP7820423B2 (ja) | 2018-02-23 | 2024-02-06 | 選択的なタンパク質分解を誘導するための低分子およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514958A JP2021514958A (ja) | 2021-06-17 |
| JP2021514958A5 true JP2021514958A5 (https=) | 2023-07-24 |
| JP7472026B2 JP7472026B2 (ja) | 2024-04-22 |
Family
ID=67687887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544488A Active JP7472026B2 (ja) | 2018-02-23 | 2019-02-22 | 選択的なタンパク質分解を誘導するための低分子およびその使用法 |
| JP2024016079A Active JP7820423B2 (ja) | 2018-02-23 | 2024-02-06 | 選択的なタンパク質分解を誘導するための低分子およびその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016079A Active JP7820423B2 (ja) | 2018-02-23 | 2024-02-06 | 選択的なタンパク質分解を誘導するための低分子およびその使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11802132B2 (https=) |
| EP (1) | EP3755325A4 (https=) |
| JP (2) | JP7472026B2 (https=) |
| CN (1) | CN112020358A (https=) |
| AU (1) | AU2019225166B2 (https=) |
| CA (1) | CA3090417A1 (https=) |
| WO (1) | WO2019165229A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102455171B1 (ko) | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 |
| US10254389B2 (en) | 2015-11-06 | 2019-04-09 | Artilux Corporation | High-speed light sensing apparatus |
| US10886309B2 (en) | 2015-11-06 | 2021-01-05 | Artilux, Inc. | High-speed light sensing apparatus II |
| US10418407B2 (en) | 2015-11-06 | 2019-09-17 | Artilux, Inc. | High-speed light sensing apparatus III |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US11105928B2 (en) | 2018-02-23 | 2021-08-31 | Artilux, Inc. | Light-sensing apparatus and light-sensing method thereof |
| US11482553B2 (en) | 2018-02-23 | 2022-10-25 | Artilux, Inc. | Photo-detecting apparatus with subpixels |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| US10886311B2 (en) | 2018-04-08 | 2021-01-05 | Artilux, Inc. | Photo-detecting apparatus |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| EP3807272A1 (en) | 2018-06-13 | 2021-04-21 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting rpn11 |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11691984B2 (en) | 2018-10-12 | 2023-07-04 | The Scripps Research Institute | Compounds and methods for DCAF-mediated protein degradation |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN120574283A (zh) | 2019-04-05 | 2025-09-02 | 凯麦拉医疗公司 | Stat降解剂和其用途 |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| MX2022006861A (es) | 2019-12-04 | 2022-07-11 | Scripps Research Inst | Agonistas del receptor glp2 y metodos de uso. |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| WO2021126973A1 (en) * | 2019-12-17 | 2021-06-24 | Orionis Biosciences, Inc. | Compounds modulating protein recruitment and/or degradation |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| KR20220119415A (ko) | 2019-12-20 | 2022-08-29 | 씨4 테라퓨틱스, 인코포레이티드 | Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물 |
| EP4081308A4 (en) | 2019-12-23 | 2024-01-24 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| KR20230005160A (ko) | 2020-03-19 | 2023-01-09 | 카이메라 쎄라퓨틱스 인코포레이티드 | Mdm2 분해제 및 이의 용도 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| US12171768B2 (en) | 2021-02-15 | 2024-12-24 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| JP2024513566A (ja) * | 2021-04-09 | 2024-03-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | 標的基質の選択的修飾のための二官能性分子 |
| US20240245787A1 (en) | 2021-04-13 | 2024-07-25 | President And Fellows Of Harvard College | E3 ligase binders and uses thereof |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| KR20240032010A (ko) | 2021-06-09 | 2024-03-08 | 더 스크립스 리서치 인스티튜트 | 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법 |
| WO2023283130A1 (en) | 2021-07-04 | 2023-01-12 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| CA3249074A1 (en) | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS |
| EP4735438A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras |
| EP4735452A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090053245A1 (en) | 2007-05-29 | 2009-02-26 | Mutz Mitchell W | Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood |
| EP2667196A1 (en) | 2012-05-26 | 2013-11-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bioorthogonal chemical inducers of reversible dimerization for control of protein interactions in cells |
| WO2014182744A1 (en) | 2013-05-08 | 2014-11-13 | The Johns Hopkins University | Novel bis-benzylidine piperidone proteasome inhibitor with anticancer activity |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP4242304A3 (en) | 2015-10-01 | 2024-02-07 | Revolution Medicines, Inc. | Methods and reagents for analyzing protein-protein interfaces |
-
2019
- 2019-02-22 CA CA3090417A patent/CA3090417A1/en active Pending
- 2019-02-22 CN CN201980027535.9A patent/CN112020358A/zh active Pending
- 2019-02-22 AU AU2019225166A patent/AU2019225166B2/en active Active
- 2019-02-22 US US16/969,772 patent/US11802132B2/en active Active
- 2019-02-22 EP EP19757828.9A patent/EP3755325A4/en active Pending
- 2019-02-22 JP JP2020544488A patent/JP7472026B2/ja active Active
- 2019-02-22 WO PCT/US2019/019180 patent/WO2019165229A1/en not_active Ceased
-
2024
- 2024-02-06 JP JP2024016079A patent/JP7820423B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514958A5 (https=) | ||
| JP2021514955A5 (https=) | ||
| RU2497807C2 (ru) | Карбазольные соединения и терапевтические применения соединений | |
| RU2386622C2 (ru) | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы | |
| JP2009536620A5 (https=) | ||
| RU2327695C2 (ru) | Ингибиторы фактора ингибирования миграции макрофага и способы для их идентификации | |
| JP2022533398A5 (https=) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| FI3848027T3 (fi) | Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita | |
| JP2022506887A5 (https=) | ||
| JP2016518437A5 (https=) | ||
| JP2015531773A5 (https=) | ||
| JP2017507160A5 (https=) | ||
| JP2018507238A5 (https=) | ||
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| JP2012511588A5 (https=) | ||
| RU2015101106A (ru) | Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения | |
| JP2009532453A5 (https=) | ||
| RU2000120162A (ru) | Арил- и гетероарилзамещенные гетероциклические производные мочевины, способ лечения заболевания, опосредованного киназой raf, фармацевтическая композиция | |
| NO20070032L (no) | Hetroarylbenzamid-derivater for anvendelse som GLK-aktivatorer ved behandling av diabetes | |
| RU2007139634A (ru) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения | |
| JP2018515525A5 (https=) | ||
| JP2018528942A5 (https=) | ||
| RU2016101958A (ru) | Пиразольные соединения в качестве модуляторов fshr и их применение | |
| RU2009101972A (ru) | Комбинации, содержащие стауроспорины |